Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the diarylthioethers class and is an adenine derivative. It was developed as an experimental inhibitor of heat shock protein HSP90 (including HSP90-alpha and its yeast homolog HSP82). The molecule binds to the ATP-binding site of HSP90, inhibiting its chaperone function. This mechanism disrupts the folding and stability of client proteins involved in cell growth and survival pathways—making it a potential candidate for anticancer drug development. However, there are no known clinical trials or approved indications for this compound as of now[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)-adenine.